References
- D'Amore P. A., Thompson R. W. Mechanisms of angiogenesis. Ann. Rev. Physiol. 1987; 49: 453–464
- Matter A. Tumor angiogenesis as a therapeutic target. Drug Discov. Today 2001; 6(19)1005–1024, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sheskin J. Thalidomide in the treatment of lepra reaction. Clin. Pharmacol. Ther. 1965; 6: 303–306
- Benzaquen L. R., Brugnara H. R., Byers S., Gattom-Celli, Halperin J. A. Clotrimazole inhibits cell proliferation in vitro and in vivo. Nat. Med. 1995; 1(6)534–540, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- D'Amato R. J., Loughnan M. S., Flynn E., Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 1994; 91: 4082–4085, [PUBMED], [INFOTRIEVE], [CSA]
- Kruse F. E., Joussen K., Rohrschneider K., Becker M. B., Volicker H. E. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefe Arch. Clin. Exp. Ophtalmol. 1998; 236: 461–466, [CROSSREF], [CSA]
- Aktas H., Fluckiger R., Acosta J. A., Savage J. M., Palakurthi S. S., Halperini J. A. Depletion of intracellular Ca2 + stores, phosphorylation of eIF2α, and sustained inhibition of translation initiation mediate the anticancer effects of clotrimazole. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 8280–8285, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Dvorak F. H. Tumors: wounds that do not heal. N. Eng. J. Med. 1986; 315: 1656–1659
- Balkwill F., Mantovani A. Inflammation and cancer: back to virchow?. Lancet 2001; 357: 539–545, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Griffioen A., Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol. Rev. 2000; 52: 237–268, [PUBMED], [INFOTRIEVE]
- Passaniti A., Taylor R. M., Pili R., et al. A simple, quantitative method for assessing angiogenesis and antiangiogenesis agents using reconstituted basement membrane, heparin and fibroblast growth factor. Lab. Invest. 1992; 67(4)519–528, [PUBMED], [INFOTRIEVE], [CSA]
- Lage A. P., Andrade S. P. Assessment of angiogenesis and tumor growth in conscious mice by a fluorimetric method. Microvasc. Res. 2000; 59: 278–285, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bailey P. J. Sponge implants as models. Methods Enzymol. 1988; 162: 327–334, [PUBMED], [INFOTRIEVE]
- Belo A. V., Ferreira M. A.N.D., Bosco A. A., Machado R. D.P., Andrade S. P. Differential effects of thalidomide on angiogenesis and tumor growth in mice. Inflammation 2001; 25(2)91–96, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Fecchio D., Sirois P., Russo M., Jancar S. Studies on inflammatory response induced by Ehrlich tumor in mice peritoneal cavity. Inflammation 1990; 14: 125–132, [PUBMED], [INFOTRIEVE]
- Kohn E. C., Liotta L. A. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res. 1995; 55: 1856–1862, [PUBMED], [INFOTRIEVE]
- Bauer K. S., Cude K. J., Dixon S. C., Kruger E. A., Figg W. D. Carboxyamido-triazole inhibits angiogenesis by blocking the calcium-mediated nitric oxide synthase-vascular endothelial growth factor pathway. J. Pharmacol. Exp. Ther. 2000; 292: 31–37, [PUBMED], [INFOTRIEVE], [CSA]
- Kenyon B. M., Browne F., D'Amato R. J. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp. Eye Res. 1997; 64: 971–978, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Verheul H. M.W., Panigrahy D., Yuan J., D'Amato R. J. Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits. Br. J. Cancer 1999; 79(1)114–118, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Gutman M., Szold A., Lazouskas T., Merimsky O., Klausner J. M. Failure of thalidomide to inhibit tumor growth and angiogenesis in vivo. Anticancer Res. 1996; 16: 3673–3678, [PUBMED], [INFOTRIEVE], [CSA]
- Minchinton A. I., Fryer K. H., Wendt K. R., Clow K. A., Hayes M. M.M. The effect of thalidomide on experimental tumors and metastases. Anticancer Drugs 1996; 7: 339–343, [PUBMED], [INFOTRIEVE], [CSA]
- Scapini P., Nesi L., Morini M., et al. Generation of biologically active angiostatin kringle 1–3 by activated human neutrophils. J. Immunol. 2002; 168(11)5798–5804, [PUBMED], [INFOTRIEVE]
- Ono M., Torisu H., Fukushi J., Nishie A., Kuwano M. Biological implications of macrophage infiltration in human tumor angiogenesis. Cancer Chemother. Pharmacol. 1999; 43: S69–S71, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Crowther M., Brown N. J., Bishop E. T., Lewis C. E. Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors. J. Leukoc. Biol. 2001; 70: 478–490, [PUBMED], [INFOTRIEVE], [CSA]
- Luo J. C., Yamaguchi S., Shitara K., Shibuya M. Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumors. Cancer Res. 1998; 54: 2652–2658
- Morales J. R., Vélez D., Subiza J. L. Ehrlich tumor stimulates extramedullar hematopoiesis in mice without secreting identifiable colony-stimulating factors and without engagement of host T cell. Exp. Hematol. 1999; 27: 1757–1767, [CROSSREF], [CSA]
- Tarabolette G., Margosio B. Antiangiogenic and antivascular therapy for cancer. Curr. Opin. Pharmacol. 2001; 1: 378–384, [CROSSREF], [CSA]